Lisa Earnhardt is currently the President and Chief Executive Officer of Intersect ENT, a venture-backed medical device innovator of treatment alternatives for Ear, Nose and Throat surgeons and their patients. Intersect’s first product, the Propel™ steroid-releasing implant, offers localized, controlled drug delivery for chronic sinusitis patients.
Prior to joining Intersect, Lisa was the President of Boston Scientific’s Cardiac Surgery division with $200M in revenue and over 450 employees. She played an instrumental role in the sale of that business in January 2008 (now known as Maquet Cardiovascular). Previously, Lisa held a variety of sales and marketing roles of increasing responsibility at Guidant leading global product launches and driving adoption of new technologies.
Lisa began her career at APM/CSC Healthcare in San Francisco where she provided management consulting services to healthcare provider organizations. She received a Bachelor of Science in industrial engineering from Stanford University, and holds an MBA from Northwestern’s Kellogg School of Management. Lisa serves on the boards of Intersect ENT and the Kellogg Alumni Council and is a member of the Young Presidents’ Organization. She is a former Director of Kensey Nash (NASDAQ: KNSY, acquired by DSM in June 2012).